1,3-Benzodioxolyl-N-methylbutanamine

1,3-Benzodioxolyl-N-methylbutanamine (MBDB) is a psychoactive drug and entactogen of the phenethylamine and amphetamine chemical classes. It was first synthesized by Alexander Shulgin and described in his book, PiHKAL: A Chemical Love Story. MBDB is a closely related chemical analogue of MDMA, with the only difference between the two being an ethyl group instead of a methyl group attached to the alpha carbon.

Chemistry

MBDB is a methylated derivative of 1,3-benzodioxolylbutanamine (BDB). It has a structure closely related to methylenedioxymethamphetamine (MDMA), the only difference being an ethyl group instead of a methyl group attached to the alpha carbon. Its full chemical name is 1-(1,3-benzodioxol-5-yl)-N-methylbutan-2-amine.

Pharmacology

The pharmacological mechanisms of MBDB are not well known. However, it is believed to act as a serotonin releasing agent (SRA), similar to its analogue MDMA. This means it induces the release of serotonin in the brain, leading to mood elevation and feelings of empathy.

Effects

The effects of MBDB are often compared to those of MDMA, but they are not identical. MBDB is reported to produce a mixture of entactogenic and stimulant effects, but without the same level of hallucinogenic effects produced by MDMA. Users often report feelings of increased energy, euphoria, and empathy.

Legal Status

The legal status of MBDB varies by country. In the United States, it is classified as a Schedule I controlled substance, making it illegal to manufacture, distribute, or possess without a license. In the United Kingdom, it is a Class A drug under the Misuse of Drugs Act.

See Also

• MDMA
• Methylone
• Methylenedioxyamphetamine
• Alexander Shulgin